Locally advanced lung cancer
My disease is locally advanced and has not spread far. What options are usually discussed?
In locally advanced disease, discussions often combine radiotherapy and systemic therapy, with the sequence depending on the condition and markers.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
What changes at this stage
- Lymph node involvement determines the staging group and initial choice.
- Some cases consider concomitant therapy with radiotherapy and systemic drugs.
- PD-L1 status and other markers may influence systemic choices.
Options that are usually discussed
Concomitant therapy
Radiotherapy and systemic therapy were administered within the same period to eligible patients.
Sequential therapy
In some conditions, therapy is given sequentially due to tolerance considerations.
Continue therapy after control
Once the disease is under control, regular monitoring and possible follow-up therapy are discussed.
The decision remains with your doctor
Practical next steps
- Ask whether the plan is to use concurrent or sequential therapy.
- Ensure lung function and general condition are evaluated.
- Ask how responses will be graded.
Questions for your oncologist
- Are my therapies administered concurrently or sequentially, and why?
- Am I eligible for concurrent therapy?
- How is monitoring during radiotherapy carried out?
- What is the plan if the disease becomes active again?
Treatment categories
Clinical trials
Registry studies for this group
International-patient access and site readiness have not been verified for any study.
NCT03191149Phase 2Targeted therapy
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Lung Cancer | biomarker: EGFR | Targeted therapy
United States347 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT03191149Not verified
NCT03460977Phase 1Combination regimen
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
United States, Bulgaria, China +584 registry sites
Why this appears: Appears because it is recorded for Lung Cancer.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT03460977Not verified
NCT04267848Phase 3Immunotherapy
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Cancer | Immunotherapy, Chemotherapy
United States, Guam1151 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT04267848Not verified
NCT05636969Not applicableCombination regimen
Multimodal Prehabilitation in Patients With Lung Cancer Undergoing Neoadjuvant Therapy
Spain1 registry sites
Why this appears: Appears because it is recorded for Lung Cancer.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05636969Not verified
Would you like to discuss this situation with someone?
Send a request with the context from this page so the documents and questions to prepare can be identified sooner.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- ALK
Biomarker
Reason: Related through a biomarker
- EGFR
Biomarker
Reason: Related through a biomarker
- Lung Cancer
Cancer type
Reason: Has a decision situation
- Metastatic lung cancer
Decision situation
Reason: Mendahului
- After lung cancer surgery
Decision situation
Reason: Menyusul
- Understanding clinical trials: terms, phases, and how to check early fit
Guide
Reason: Related to this page
To check
- Immunotherapy
Treatment category
Reason: Mungkin memerlukan
- Chemotherapy
Treatment category
Reason: Mungkin memerlukan
- Radiotherapy
Treatment category
Reason: Mungkin memerlukan
- Precision radiotherapy (IMRT and VMAT)
Treatment category
Reason: Mungkin memerlukan
- Targeted therapy
Treatment category
Reason: Mungkin memerlukan
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.